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Background: The purpose of this study was to elucidate impact of annulus ellipticity on clinical outcomes after transcatheter aortic valve 
implantation (TAVI).
methods: Of 548 patients included in our TAVI database with either of the Edwards or CoreValve (October 2006 to June 2012), 305 consecutive 
patients undergoing pre-procedural multidetector computed tomography (MDCT) were analyzed. Ellipticity was defined as “long/short-axis MDCT-
measured diameter ratio>1.20”. We compared clinical outcomes in patients with (n=155) vs. without (n=150) ellipticity.
results: Patients were 83.2±6.6 years old and EuroSCORE was 19.9±12.0%. The ellipticity group was similar to the non-ellipticity group except for 
coronary disease (49.0vs64.0%,P=0.01). Despite no significant difference in mean MDCT-measured diameter (23.7±2.1vs23.8±2.1mm,P=0.47), 
ellipticity was associated with decreased short-axis (21.3±2.0vs22.5±2.0mm,P<0.01) and increased long-axis diameter 
(27.0±2.5vs25.7±2.5mm,P<0.01) resulting in increased long/short-axis diameter ratio (1.27±0.07vs1.14±0.06mm,P<0.01). Ellipticity group 
tended to have increased incidence of bicuspid valve (12.3%vs6.0%,P=0.06). The CoreValve was used similarly (21.3vs22.0%,P=0.88). There was 
no significant difference in device success (94.2vs93.3%,P=0.76), risk of annulus rupture (1.3vs0.7%,P=0.51) or valve migration (0vs2.0%,P=0.12) 
between 2 groups. Post-procedural mean gradient (10.1±6.1vs9.7±3.7mmHg,P=0.52), aortic regurgitation ≥2/4 (15.5vs17.3%,P=0.66), 30-day 
mortality (5.8vs10.0%,P=0.17) and 30-day combined safety point (14.2vs14.7%,P=0.91) were also similar in both groups.
conclusions: In patients with ellipticity, TAVI is associated with equally high rates of success, low complication rates, similar efficacy and 
acceptable outcomes as in non-ellipticity patients.
